|本期目录/Table of Contents|

[1]杨蓉,叶贝贝,闫云飞,等.术前诱导化疗治疗局部晚期喉癌的远期疗效观察[J].天津医科大学学报,2020,26(04):354-357.
　YANG Rong,YE Bei-bei,YAN Yun-fei,et al.Observation of the long-term efficacy of preoperative induction chemotherapy on locally advanced laryngeal cancer[J].Journal of Tianjin Medical University,2020,26(04):354-357.
点击复制

术前诱导化疗治疗局部晚期喉癌的远期疗效观察(PDF)
分享到：

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
26卷
期数:
2020年04期
页码:
354-357
栏目:
临床医学
出版日期:
2020-07-15

文章信息/Info

Title:
Observation of the long-term efficacy of preoperative induction chemotherapy on locally advanced laryngeal cancer
文章编号:
1006-8147(2020)04-0354-04
作者:
杨蓉; 叶贝贝; 闫云飞; 张文超
（天津医科大学肿瘤医院颌面耳鼻喉肿瘤科，国家肿瘤临床医学研究中心，天津市“肿瘤防治”重点实验室，天津市恶性肿瘤临床医学研究中心，天津 300060）
Author(s):
YANG Rong;  YE Bei-bei;  YAN Yun-fei;  ZHANG Wen-chao
（Department of Maxillofacial and Otorhinolaryngology Oncology, Cancer Institute and Hospital, Tianjin Medical University, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin?謘s Clinical Research C
关键词:
喉肿瘤; 化疗; 手术
Keywords:
laryngeal neoplasm;  induction chemotherapy;  surgery
分类号:
R739.65
DOI:
-
文献标志码:
A
摘要:
目的：探讨术前诱导化疗对于局部晚期喉癌（T3-4N0-3M0）的远期疗效。方法：回顾性分析162例局部晚期喉癌患者的临床及随访资料，其中94例行术前诱导化疗（TPF方案），68例直接手术，统计并分析两种治疗方式的生存结果。结果：中位随访时间为 63个月（36~100个月），术前诱导化疗组与直接手术组生存率分别为57.4%、50.0%（P>0.05），无病生存率分别为52.1%、36.8%（P<0.05）。术前诱导化疗组与直接手术组局部复发率分别为17.0%、30.9%（P<0.05），远处转移率分别为10.6%、16.2%（P>0.05）。多因素分析显示与术前诱导化疗组相比，直接手术组死亡风险增加（HR=1.668，P<0.05）。结论：术前诱导化疗可降低局部晚期喉癌患者的局部复发率，生存获益仍需临床前瞻性研究进一步证实。
Abstract:
Objective: To investigate the long-term efficacy of preoperative induction chemotherapy on locally advanced laryngeal cancer (T3-4N0-3M0). Methods: The clinical and follow-up data of 162 patients with locally advanced laryngeal cancer were retrospectively analyzed. Among them, 94 patients obtained preoperative induction chemotherapy(TPF scheme), and 68 were given direct surgical treatment. The survival outcomes of both treatments were recorded and analyzed respectively. Results: The median follow-up time was 63 months (36-100 months). The survival rates of the preoperative induction chemotherapy group and the direct surgery group were 57.4% and 50.0% (P> 0.05), respectively; and the disease-free survival rates were 52.1% and 36.8% (P<0.05), respectively. The local recurrence rates of the preoperative induction chemotherapy group and the direct surgery group were 17.0% and 30.9%(P<0.05), respectively; the distant metastasis rates were 10.6% and 16.2% (P>0.05), respectively. Besides, multivariate analysis showed that compared with the preoperative induction chemotherapy group, the risk of death was increased in the direct surgery group(HR=1.668, P<0.05). Conclusion: Preoperative induction chemotherapy can reduce the local recurrence rate of patients with locally advanced laryngeal cancer, but the survival benefit still needs to be further confirmed by prospective clinical studies.

参考文献/References:

[1] Colevas A D, Yom S S, Pfister D G, et al. NCCN guidelines insights: head and neck cancers, version 1.2018 [J]. J Natl Compr Canc Netw, 2018, 16(5):479
[2] Gao P, Gong L, Wang X. Induction chemotherapy in patients with resectable laryngeal cancer: a meta-analysis[J]. Mol Clin Oncol, 2018, 9(2):155
[3] Al-Gilani M, Skillington S A, Kallogjeri D, et al. Surgical vs nonsurgical treatment modalities for T3 glottic squamous cell carcinoma[J]. JAMA Otolaryngol Head Neck Surg, 2016, 142(10):940
[4] Grover S, Swisher-McClure S, Mitra N, et al. Total laryngectomy versus larynx preservation for T4a larynx cancer: patterns of care and survival outcomes[J]. Int J Radiat Oncol Biol Phys, 2015, 92(3):594
[5] Nakashima T, Yasumatsu R, Asai K, et al. Single-cycle induction chemotherapy for resectable advanced hypopharyngeal cancer[J]. Int J Clin Oncol, 2017, 22(3):442
[6] Huguet F, Schick U, Pointreau Y. Role of induction chemotherapy in head and neck cancer: Cons [J]. Cancer Radiother, 2017, 21(6-7):510
[7] Department of Veterans Affairs Laryngeal Cancer Study Group, Wolf G T, Fisher S G, et al. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer [J]. N Engl J Med, 1991, 324(24):1685
[8] Spector M E, Rosko A J, Swiecicki P L, et al. From VA Larynx to the future of chemoselection: defining the role of induction chemotherapy in larynx cancer [J]. Oral Oncol, 2018, 86:200
[9] Sittitrai P, Reunmarkkaew D, Chaiyasate S. The role of induction chemotherapy followed by surgery in unresectable stage IVb laryngeal and hypopharyngeal cancers: a case series[J]. J Otolaryngol Head Neck Surg, 2018, 47(1):62
[10] 中国抗癌协会头颈部肿瘤专业委员会，中国抗癌协会放射肿瘤专业委员会. 头颈部肿瘤综合治疗专家共识[J]. 中华耳鼻喉头颈外科杂志，2010，45（7）：535
[11] Smee R, Williams J R, Kotevski D P. Management of locally advanced T3-4 glottic laryngeal carcinomas [J]. J Laryngol Otol, 2018, 132(7):642
[12] 张宇, 牟方彪, 骆德平. 术前诱导化疗口腔颌面恶性肿瘤的近期疗效观察[J]. 西部医学,2016, 28(4):494
[13] Zhong L P, Zhang C P, Ren G X, et al. Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma[J]. J Clin Oncol, 2013, 31(6):744
[14] Brandstorp-Boesen J, Sorum Falk R, Boysen M, et al. Impact of stage, management and recurrence on survival rates in laryngeal cancer [J]. PLoS One, 2017, 12(7):e0179371
[15] Luna-Oritz K, Villavicencio-Valencia V, Rodriguez-Falconi A, et al. Induction chemotherapy followed by supracricoid partial laryngectomy (SCPL) with cricohyoidoepiglottopexy (CHEP) in T3NO arytenoid fixation-related glottic cancer [J]. B-Ent, 2016, 12(4):271
[16] Ma J, Liu Y, Huang X L, et al. Induction chemotherapy decreases the rate of distant metastasis in patients with head and neck squamous cell carcinoma but does not improve survival or locoregional control: a meta-analysis [J]. Oral Oncol, 2012, 48(11):1076
[17] 陈智伟, 廖美琳. RECIST标准在肿瘤治疗疗效评价中的应用[J]. 中国肿瘤, 2004，13(10):6

相似文献/References:

[1]闫庆贺,宋世辉,彭 民,等.卡铂联合多西他赛治疗非小细胞肺癌CECs变化[J].天津医科大学学报,2014,20(05):366.
　YAN Qing-he,SONG Shi-hui,PENG Min,et al.Changes of circulating endothelial cells in non-small cell lung cancer patients treated with carboplatin plus docetaxel[J].Journal of Tianjin Medical University,2014,20(04):366.
[2]李家腾,宋世辉,王 田,等.小细胞肺癌患者化疗前后CEA、NSE和CYFRA21-1的变化对评估预后的作用[J].天津医科大学学报,2014,20(06):448.
　LI Jia-teng,SONG Shi-hui,WANG Tian,et al.Effect of Changes of CEA, NSE and CYFRA21-1 before and after chemotherapy on the evaluation of prognosis in patients with small cell lung cancer[J].Journal of Tianjin Medical University,2014,20(04):448.
[3]王冬冬,秦振邦,王晓明,等.成人I期原发睾丸畸胎瘤预后分析[J].天津医科大学学报,2016,22(03):265.
[4]仝颖娜,刘晓彬,张露方,等.血胱抑素C等对肺癌患者化疗过程中肾损伤的评价[J].天津医科大学学报,2017,23(02):143.
　TONG Ying-na,LIU Xiao-bin,ZHANG Lu-fang,et al.Evaluation of serum cystatin C in kidney function damage for patients with lung cancer during chemotherapy[J].Journal of Tianjin Medical University,2017,23(04):143.
[5]刘欣,张鹏,陈渊.肠内营养支持在食管癌术后辅助化疗患者中的临床应用[J].天津医科大学学报,2017,23(03):274.
[6]高会霞,王 彬,方 黎,等.3DCRT联合化疗对晚期NSCLC患者近期疗效及血清肿瘤标记物的影响[J].天津医科大学学报,2019,25(05):507.

备注/Memo

备注/Memo:
基金项目 天津市卫生局科技基金资助项目（2011Kz75） 作者简介 杨蓉(1990-)，女，硕士在读，研究方向：颌面耳鼻喉肿瘤学；
通信作者：张文超，E-mail：zwbeyond_999@sina.com。
更新日期/Last Update: 2020-07-15